Leucadia launches generic Migranal

Sandra Levy
Senior Editor
Sandra Levy profile picture

Leucadia Pharmaceuticals is releasing dihydroergotamine mesylate nasal spray.

The product is used for the acute treatment of migraine headaches with or without aura.

It the first generic of Bausch Health’s Migranal. 

“Dihydroergotamine mesylate nasal spray is the latest example of Leucadia’s continued commitment to providing safe, effective solutions that increase patient quality of life,” said William Larkins, CEO of Leucadia Pharmaceuticals’ parent company, Custopharm. 

Larkins added, "This generic is Leucadia’s third product since April 2019 to receive first generic approval from the Food and Drug Administration, a unique achievement that serves as a testament to the tireless work of our dedicated team. Leucadia continues to prioritize the development of high barrier products and this latest first generic launch demonstrates that yet again.”